The government is targeting 1,200 technical collaborations between Japanese companies and Indian investors for over Rs 42,000 crore, 200 joint ventures with overseas investors for Rs 14,000 crore, and another Rs 14,000-crore investment from about 50 multinational companies.

The industry feels two factors have played a role in improving the offtake and reducing trade inventory - one is that the supply chain in pharmaceuticals has more or less stabilised, and secondly, with lockdown curbs easing and OPDs opening, some demand has grown at the consumer end as well.

Cipla is among the three Indian companies that signed a non-exclusive licensing agreement with US-based Gilead Sciences to make and distribute the latter's repurposed Ebola drug Remdesivir in 127 countries including India.

Pharma companies gear up for the 'new normal' as they train and align their sales forces for a paradigm shift. GSK leads the charge with staggered return-to-work, others plans yoga sessions and health care webinars for salesperson's family.

Researchers at Northwell Health in New York are testing the effects on Famotidine (used in high intravenous doses) on Covid-19 patients as a potential treatment. After the hospital announced its clinical trials, it led to a drug shortage in the US. Back home, however, there has not been any surge in the demand for Famotidine yet.

The hospital, in the commercial hub of Bandra-Kurla Complex, will serve as an isolation facility for non-critical COVID-19 patients. Expected to be ready in a fortnight, the new makeshift facility can be scaled up to 5,000 beds, if needed. The Brihanmumbai Municipal Corporation will run the hospital that will have, among other things, oxygen facilities and pathological laboratories. Sohini Das reports.

Although there is no government order to this effect, chemists decide to not dispense medicines for cold, cough and fever over the counter.

A dipstick survey covering 30 villages in Rajasthan threw up some worrisome numbers. About 250 children missed their regular vaccination schedule in March alone. These numbers are alarming, since India has around 600,000 villages according to the 2011 census. Sohini Das reports.

Can Interferon alfa-2b treat COVID-19 effectively?

Cadila, Biocon developing rapid antibody testing kits; Eris, Mylan, Gland importing. There are two kinds of testing for the novel coronavirus - the real-time polymerase chain reaction test kit that uses throat or nasal swabs and provides results in a few hours, and the other is antibody-based rapid testing kit that use blood samples and provides results in a few minutes.

Private diagnostic laboratories have already approached the respective state governments and the municipalities where they are operating to approve protocols for such testing in clusters, reports Sohini Das.

A leading exporter said, there is enough stock of paracetamol in the country. At present, the US, which has become the epicentre of the COVID-19 outbreak, needs paracetamol. He further said India would lose its credibility as the "pharmacy of the world" if it adopts protectionist policies during such a crisis.

The ICMR has already approved a bunch of rapid test kits for launch. The health ministry admitted that clusters of COVID-19 had appeared in many states and the risk of further spread remains very high.

The test used now, called PCR (or polymerace chain reaction), uses a nasal or throat swab sample and identifies the virus. These tests take at least five hours to give results. The rapid test, on the other hand, uses a blood sample and gives results based on detecting the presence of certain antibodies that react to the coronavirus protein.

The Central Drugs Standard Control Organisation said while the rights, safety, and well-being of trial subjects were of paramount importance, protocol amendment, deviation or modification might be necessary in some cases owing to unavoidable circumstances.

The ICMR is working on a war footing to develop the testing ecosystem -- especially for the screening blood tests. NIV, Pune, is in the process of validating antibody-based screening kits.

The telecast was viewed by 197 million Indians, higher than the Indian Premier League final which was watched by 133 million, reports Sohini Das.

At present, the cost of testing for COVID-19 is Rs 4,500 per examination and the results are available within 24 hours. Almost 90 per cent of queries fizzle out after patients realise the cost of testing will not be borne by the government.

Medicines that fall under Schedule H category (class of prescription drugs) would be provided against a valid prescription that can be submitted either physically or over e-mail. Narcotics, psychotropics and controlled substances, though, cannot be delivered.

Exports of 13 APIs - including paracetamol, tinidazole, metronidazole, vitamin B1, vitamin B6, vitamin B12, acyclovir, progesterone - along with formulations made from these APIs, would be restricted.